Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Full-length dystrophin expression in half of the heart cells ameliorates -isoproterenol-induced cardiomyopathy in mdx mice

15 Jun 2004

Abstract excerpt

Gene therapy holds great promise for curing Duchenne muscular dystrophy (DMD), the most common fatal inherited childhood muscle disease. Success of DMD gene therapy depends upon functional improvement in both skeletal and cardiac muscle. Numerous gene transfer studies have been performed to correct skeletal muscle pathology, yet little is known about cardiomyopathy gene therapy. Since complete transduction of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscle Physiology and Disorders
Share to Viral Infections and Immunology Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15190010
DOI: 10.1093/hmg/ddh174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Full-length dystrophin expression in half of the heart cells ameliorates -isoproterenol-induced cardiomyopathy in mdx micePMID 15190010Read ↗

DMD carrier model with mosaic dystrophin expression in the heart reveals complex vulnerability to myocardial injury.Semantic proximity Read ↗

Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapySemantic proximity Read ↗

Functional cardiac consequences of β-adrenergic stress-induced injury in the <i>mdx</i> mouse model of Duchenne muscular dystrophySemantic proximity Read ↗

Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathySemantic proximity Read ↗

Cardiac Cell and Animal Models for Duchenne Muscular Dystrophy in the Era of Gene Therapy and Precision MedicineSemantic proximity Read ↗

Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophySemantic proximity Read ↗

Low dystrophin levels in heart can delay heart failure in mdx miceSemantic proximity Read ↗

Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila.Semantic proximity Read ↗

Gene Therapy Targets in Heart Failure: The Path to TranslationSemantic proximity Read ↗

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers†Semantic proximity Read ↗

Microdystrophin Gene Therapy of Cardiomyopathy Restores Dystrophin-Glycoprotein Complex and Improves Sarcolemma Integrity in the <i>Mdx</i> Mouse HeartSemantic proximity Read ↗

A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.